Medical breakthroughs from using existing drugs in new ways await discovery--if manufacturers have an incentive to pursue them.

Former Speaker of the House Newt Gingrich points out that when government levies a tax, businesses will not ultimately pay it--consumers will.

Anupam B. Jena and Tomas J. Philipson argue that further use of cost-effectiveness analysis to curb health care spending may do more harm than good.

Drugs developed by the pharmaceutical research industry have revolutionized health care. Yet, in recent years there has been a decline in the number of innovative new drugs reaching the market, despite extraordinary advances in the basic and applied science upon which these new developments depend. Why is that? Panelists...

At this event, John A. Vernon and Joseph H. Golec will discuss their new AEI Press book.

Lower earnings announcements for the pharma sector last week stem from two provisions in the health reform legislation.

In a recent working paper, World Population Prospects and the Global Economic Outlook, AEI political economist and demographer Nicholas Eberstadt examines global demographic prospects up to 2030 and assesses the impact that these population trends will have on the world's economic performance.

"We are at the cusp of a revolution in medicine and biotechnology," Sonia Arrison announces in "100+", "that will radically increase not just our life spans but also, and more importantly, our health spans." This revolution will "change everything, from careers and relationships to family and faith."